



# Are You Ready for a Successful Clinical Research Audit?

*A BRANY Info Post:*

Common Areas Where Our  
Auditors Find Significant  
Issues During Quality  
Assurance Reviews



*To be audit prepared, make sure to review...*



## # 1: Delegation and PI Oversight

- **Key Aspects of a Delegation of Authority (DoA) Log:**
  - Ensure delegation of tasks are documented clearly (e.g. start and end dates, PI authorization via initials or signature)
  - Study personnel have appropriate qualifications prior to study start and are adequately trained throughout.
  - Periodic review to confirm accuracy and completeness, clarifying any discrepancies with start and end dates
  - Ensure appropriate delegation of tasks
- **Principal Investigator (PI) Overall Responsibility:**
  - Ultimately accountable for oversight and study conduct.
  - Maintains thorough knowledge of study protocol.
  - Ensures study team are informed of protocol changes.
  - Prompt assessment of any adverse events or deviations.
  - Confirms accurate and timely documentation of all trial-related activities.

*Some of our most noted findings involve...*

## **#2: Documentation of the Informed Consent Process**




### ○ **Informed Consent:**

- Must be signed prior to completing any study specific tasks.
- Study personnel qualified and delegated are to obtain informed consent.
- Provide comprehensive information about the study.
- Must be IRB approved.

### ○ **Essentials of Consenting Process:**

- Documentation that elements of consent were captured, including interpreter information when applicable.
- Obtained in a confidential setting.
- Record of any questions asked by participants and the responses given.
- Verification of participant's comprehension and voluntary agreement to participate.

## **#3: ALCOA & Good Clinical Practice (GCP)**



**The ALCOA principles are fundamental to Good Clinical Practice (GCP) and ensure the reliability and integrity of data collected in clinical trials. Data must be:**

- **A: Attributable** – Data should be traceable to a specific individual or source.
- **L: Legible** – Data must be clear and readable.
- **C: Contemporaneous** – Data should be recorded at the time of the activity.
- **O: Original** – Data must be the first recorded instance.
- **A: Accurate** – Data should be correct and truthful.

**This rigor is crucial for maintaining the credibility of the clinical trial results, ensuring regulatory compliance, and ultimately protecting patient safety.**



Want to learn more about the quality assurance function of auditing and how to ensure your site is performing at optimal compliance?

Please email your questions to [QA@BRANY.com](mailto:QA@BRANY.com) or visit BRANY's [Research Auditing and Monitoring](#) page for more information.

